Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Read more about Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.
DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Read more about DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape.
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Read more about A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry.
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Read more about Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Read more about Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Read more about Genome-wide association studies identify four ER negative-specific breast cancer risk loci.
Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Read more about Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.
Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Read more about Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk.
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Read more about A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation.
AXL and acquired resistance to EGFR inhibitors. Read more about AXL and acquired resistance to EGFR inhibitors.
